WILL RESMETIROM PROVE TO BE A GAMECHANGER IN NASH?$MDGL Madrigal Pharmaceuticals, Inc
. (NASDAQ: MDGL) a clinical-stage biopharmaceutical company, announced positive topline results from a Phase III trial evaluating its lead candidate Resmetirom (MGL-3196), in non-alcoholic fatty liver disease (NAFLD).
The Positive Data is the first step towards its goal of becoming a potential game changer in NASH, as a lot rides on the data from the Phase 3 data from its NASH trial , which is expected later this year.
Read on to find out more! https://www.aviseanalytics.com/will-resmetirom-prove-to-be-a-gamechanger-in-nash/